(AHR) American Healthcare REIT - Overview
Stock: Senior Housing, Skilled Nursing, Outpatient Medical, Healthcare Properties
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 2.64% |
| Yield on Cost 5y | 8.19% |
| Yield CAGR 5y | 0.00% |
| Payout Consistency | 98.3% |
| Payout Ratio | 2.9% |
| Risk 5d forecast | |
|---|---|
| Volatility | 28.1% |
| Relative Tail Risk | -1.76% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 2.03 |
| Alpha | 61.15 |
| Character TTM | |
|---|---|
| Beta | 0.470 |
| Beta Downside | 0.586 |
| Drawdowns 3y | |
|---|---|
| Max DD | 11.86% |
| CAGR/Max DD | 8.49 |
Description: AHR American Healthcare REIT January 08, 2026
American Healthcare REIT, Inc. (NYSE:AHR) is a Maryland-based, self-managed REIT that owns and operates a diversified portfolio of clinical-healthcare real estate across the United States, the United Kingdom, and the Isle of Man. Its assets span senior housing, skilled nursing facilities (SNFs), outpatient medical (OM) buildings, and other healthcare-related properties, with senior-housing operations run under the RIDEA structure.
The company leverages a fully integrated management platform to both own and operate properties, while also originating and acquiring secured loans and pursuing opportunistic real-estate investments. It focuses on income-generating assets and selectively develops new healthcare properties, maintaining REIT tax status under the U.S. Internal Revenue Code.
Key sector drivers include an aging U.S. population (the 65+ cohort is projected to reach 22% of the population by 2035) and sustained demand for post-acute care services, which support occupancy rates that have averaged above 92% for AHR’s senior-housing portfolio over the past 12 months. Recent quarterly filings show a Funds From Operations (FFO) growth of 7% YoY, and a weighted-average lease term of 8.5 years, providing earnings visibility.
Investors should monitor Medicare reimbursement trends and the competitive landscape of specialty-care REITs, as these factors materially affect rental growth and asset valuations.
For a deeper, data-driven look at AHR’s valuation metrics and scenario analysis, consider exploring the research tools available on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income: 27.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 4.47 > 1.0 |
| NWC/Revenue: -20.66% < 20% (prev 5.36%; Δ -26.02% < -1%) |
| CFO/TA 0.06 > 3% & CFO 298.8m > Net Income 27.3m |
| Net Debt (1.55b) to EBITDA (292.6m): 5.30 < 3 |
| Current Ratio: 0.46 > 1.5 & < 3 |
| Outstanding Shares: last quarter (162.9m) vs 12m ago 21.82% < -2% |
| Gross Margin: 20.69% > 18% (prev 0.20%; Δ 2049 % > 0.5%) |
| Asset Turnover: 46.55% > 50% (prev 42.99%; Δ 3.56% > 0%) |
| Interest Coverage Ratio: 0.00 > 6 (EBITDA TTM 292.6m / Interest Expense TTM 66.09b) |
Altman Z'' -2.33
| A: -0.10 (Total Current Assets 393.4m - Total Current Liabilities 847.7m) / Total Assets 4.77b |
| B: -0.32 (Retained Earnings -1.52b / Total Assets 4.77b) |
| C: 0.02 (EBIT TTM 84.1m / Avg Total Assets 4.72b) |
| D: -0.74 (Book Value of Equity -1.52b / Total Liabilities 2.05b) |
| Altman-Z'' Score: -2.33 = D |
Beneish M 0.62
| DSRI: 0.68 (Receivables 188.6m/253.9m, Revenue 2.20b/2.01b) |
| GMI: 0.97 (GM 20.69% / 20.00%) |
| AQI: 7.63 (AQ_t 0.89 / AQ_t-1 0.12) |
| SGI: 1.09 (Revenue 2.20b / 2.01b) |
| TATA: -0.06 (NI 27.3m - CFO 298.8m) / TA 4.77b) |
| Beneish M-Score: 0.62 (Cap -4..+1) = D |
What is the price of AHR shares?
Over the past week, the price has changed by +3.97%, over one month by +3.48%, over three months by +2.31% and over the past year by +70.33%.
Is AHR a buy, sell or hold?
- StrongBuy: 4
- Buy: 4
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the AHR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 56.1 | 15% |
| Analysts Target Price | 56.1 | 15% |
| ValueRay Target Price | 64.1 | 31.4% |
AHR Fundamental Data Overview February 05, 2026
P/E Forward = 55.8659
P/S = 4.091
P/B = 3.2052
Revenue TTM = 2.20b USD
EBIT TTM = 84.1m USD
EBITDA TTM = 292.6m USD
Long Term Debt = 1.01b USD (from longTermDebt, last quarter)
Short Term Debt = 549.7m USD (from shortTermDebt, last quarter)
Debt = 1.70b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.55b USD (from netDebt column, last quarter)
Enterprise Value = 10.52b USD (8.97b + Debt 1.70b - CCE 147.4m)
Interest Coverage Ratio = 0.00 (Ebit TTM 84.1m / Interest Expense TTM 66.09b)
EV/FCF = 39.11x (Enterprise Value 10.52b / FCF TTM 269.1m)
FCF Yield = 2.56% (FCF TTM 269.1m / Enterprise Value 10.52b)
FCF Margin = 12.24% (FCF TTM 269.1m / Revenue TTM 2.20b)
Net Margin = 1.24% (Net Income TTM 27.3m / Revenue TTM 2.20b)
Gross Margin = 20.69% ((Revenue TTM 2.20b - Cost of Revenue TTM 1.74b) / Revenue TTM)
Gross Margin QoQ = 20.67% (prev 21.42%)
Tobins Q-Ratio = 2.21 (Enterprise Value 10.52b / Total Assets 4.77b)
Interest Expense / Debt = 3891 % (Interest Expense 66.01b / Debt 1.70b)
Taxrate = 21.0% (US default 21%)
NOPAT = 66.4m (EBIT 84.1m * (1 - 21.00%))
Current Ratio = 0.46 (Total Current Assets 393.4m / Total Current Liabilities 847.7m)
Debt / Equity = 0.63 (Debt 1.70b / totalStockholderEquity, last quarter 2.68b)
Debt / EBITDA = 5.30 (Net Debt 1.55b / EBITDA 292.6m)
Debt / FCF = 5.76 (Net Debt 1.55b / FCF TTM 269.1m)
Total Stockholder Equity = 2.41b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.58% (Net Income 27.3m / Total Assets 4.77b)
RoE = 1.13% (Net Income TTM 27.3m / Total Stockholder Equity 2.41b)
RoCE = 2.46% (EBIT 84.1m / Capital Employed (Equity 2.41b + L.T.Debt 1.01b))
RoIC = 1.65% (NOPAT 66.4m / Invested Capital 4.03b)
WACC = 6.43% (E(8.97b)/V(10.67b) * Re(7.65%) + (debt cost/tax rate unavailable))
Discount Rate = 7.65% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 57.05%
[DCF Debug] Terminal Value 77.94% ; FCFF base≈183.3m ; Y1≈120.3m ; Y5≈54.9m
Fair Price DCF = N/A (negative equity: EV 1.50b - Net Debt 1.55b = -47.0m; debt exceeds intrinsic value)
EPS Correlation: 65.21 | EPS CAGR: 929.6% | SUE: 0.0 | # QB: 0
Revenue Correlation: 97.06 | Revenue CAGR: 13.22% | SUE: 0.93 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.14 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=3
EPS next Year (2026-12-31): EPS=0.71 | Chg30d=+0.000 | Revisions Net=+0 | Growth EPS=+39.2% | Growth Revenue=+11.2%